Advertisement
UK markets open in 51 minutes
  • NIKKEI 225

    40,003.60
    +263.20 (+0.66%)
     
  • HANG SENG

    16,531.39
    -205.71 (-1.23%)
     
  • CRUDE OIL

    82.55
    -0.17 (-0.21%)
     
  • GOLD FUTURES

    2,159.60
    -4.70 (-0.22%)
     
  • DOW

    38,790.43
    +75.63 (+0.20%)
     
  • Bitcoin GBP

    50,555.63
    -3,233.16 (-6.01%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • NASDAQ Composite

    16,103.45
    +130.25 (+0.82%)
     
  • UK FTSE All Share

    4,218.89
    -3.20 (-0.08%)
     

Novo Nordisk A/S: Share repurchase programme

Novo Nordisk A/S
Novo Nordisk A/S

Bagsværd, Denmark, 15 August 2022 – On 3 August 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022.

Under the programme initiated 3 August 2022, Novo Nordisk will repurchase B shares for an amount up to DKK 4.4 billion in the period from 4 August 2022 to 31 October 2022.

Since the announcement of the programme, the following transactions have been made:

 

Number of
B shares

Average
purchase price

Transaction
value, DKK

4 August 2022

90,000

774.61

69,715,134

5 August 2022

95,000

765.81

72,752,397

8 August 2022

90,000

752.63

67,736,306

9 August 2022

90,000

757.42

68,167,583

10 August 2022

90,000

768.12

69,131,058

11 August 2022

90,000

788.03

70,922,666

12 August 2022

90,000

783.09

70,478,526

Accumulated under the programme

635,000

 

488,903,671

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

ADVERTISEMENT

Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 29,214 B shares in the period from 4 August 2022 to 15 August 2022. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 18,253,211 B shares of DKK 0.20 as treasury shares, corresponding to 0.8% of the share capital. The total amount of A and B shares in the company is 2,280,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 24 billion during a 12-month period beginning 2 February 2022. As of 12 August 2022, Novo Nordisk has since 2 February 2022 repurchased a total of 16,542,432 B shares at an average share price of DKK 767.16 per B share equal to a transaction value of DKK 12,690,672,532

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 50,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.

Further information

Media:

 

 

Ambre Brown Morley

+45 3079 9289

abmo@novonordisk.com

Natalia Salomao Abrahao (US)

+1 848 304 1027

niaa@novonordisk.com

 

 

 

Investors:

 

 

Daniel Muusmann Bohsen

+45 3075 2175

dabo@novonordisk.com

David Heiberg Landsted

+45 3077 6915

dhel@novonordisk.com

Jacob Martin Wiborg Rode

+45 3075 5956

jrde@novonordisk.com

Mark Joseph Root (US)

+1 848 213 3219

mjhr@novonordisk.com


Company announcement No 65 / 2022

Attachment